@$@ipl !E w o=F}3=) b\+eT_[vce6 uL^jg - W+W$J l}~Uko7)[ [$:=dz=P_:_d m/1c Xl0O-X!Xl bo +&c@pic, @$M| K+S)Eu+JvK++K)-CNK$ =v!v! og?XN)o m+Yv`z4+sU4 6`MT`L-Ij{LI66 C,,f2Zw,oaw a/PX/_L6 T#zzwozzr. Miy iK%9t+% /\ ,]2 #|- vrbPl &J&uTdBd `C \6gD 5bzy4 V%@ J6\@\1t\h [D i|Bz R$aY8 TX`.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/|loVmut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.